Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T21:57:44.339Z.
Calculation as of: 2026-10-06T21:57:44.339Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4efcc2f75e7b9d1a3dd193370b83b229becf15f1f7fcdbde4bbae966de3ea950
EARNINGS YIELD
N/A
Olema Pharmaceuticals, Inc.
Market Cap
$691.79M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$694.79M
Earnings Yield
N/A
TTM Avg
0.13%
3Y Avg
0.36%
5Y Avg
0.36%
Market Cap
$685.49M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$709.65M
Earnings Yield
5.67%
TTM Avg
4.56%
3Y Avg
4.80%
5Y Avg
6.03%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | $691.79M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $693.19M | N/A | N/A | N/A | N/A |
| Wave Life Sciences Ltd. (WVE)vs › | $693.61M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $694.79M | N/A | 0.13% | 0.36% | 0.36% |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | N/A | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $681.02M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $702.82M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.65M | 5.67% | 4.56% | 4.80% | 6.03% |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 0.87% | 4.56% | 4.76% | 4.76% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
